Heart Transplant - Antibody Mediated Rejection
Therapeutic Plasma Exchange

This guideline is departmental specific and applies only to activities within the Nephrology and Cardiology programs.

1.0 Introduction

This Clinical Practice Guideline (CPG) refers to the therapeutic plasma exchange for an infant/child with evidence of Antibody Mediated Rejection (AMR) after heart transplant. The goal of TPE is to remove donor-specific antibodies and/or inflammatory mediators implicated in AMR. The number of therapeutic plasma exchanges is patient specific and is ordered by the physician responsible for the patient's care. Please see Therapeutic Plasma Exchange under related documents for CPG on procedure.

The target users of this guideline will be Nurses, Physicians within the Nephrology and Cardiology programs.

Indications: This CPG applies to infants/children who have evidence of AMR.

Contraindications: Plasma exchanges should not ordinarily be performed within 24 hours of an operative procedure. If necessary to bypass this recommendation, the Staff M.D. must document the need for the procedure in the patient chart.

2.0 Definitions

- **Fresh Frozen Plasma (FFP)** - is separated from whole blood and is frozen within eight hours of collection. FFP contains all the coagulation factors in normal concentrations. Plasma is free of red blood cells, leukocytes and platelets. Plasma also has volume expansion and oncotic properties.

- **Total Blood Volume (TBV)** - the amount of blood in the whole body, both cells and fluid. The volume of the patient's blood is based on the patient's weight. The TBV is related to lean body mass. There is a difference between children and adults with newborns having a higher TBV per kg because of their higher packed red cell volume. TBV is calculated using the following formula:

  - Neonates (0-1 month): 100 ml/kg
  - Infants/children (1 month-16 years): 80 ml/kg
  - Adolescents (16 years and older): 70 ml/kg

- **Plasma Volume** is the total volume of plasma in the body.

  - Plasma Volume = TBV (ml) X (1-hematocrit)

- **Exchange** - patient plasma is replaced by donor plasma. The exchange product can be either FFP, 5% Albumin or a combination of both.
3.0 Clinical Recommendations

Pre-exchange requirements
1. All recent post-transplant patients should be connected to cardiac monitor during plasma exchange.
2. Complete following blood work prior to the procedure:
   - CBC and differential
   - INR
   - Albumin
   - K, Na, P, Ca
   - TCO₂
3. Ensure blood work is within acceptable range
4. Complete the following blood work after the procedure:
   - INR
   - K, Na, P, Ca
   - TCO₂

Order replacement solution
Replacement solution must be compatible with the patient's serum blood type and the donor blood type. Refer to Blood Groups Required for Blood Products Administered During ABO-Incompatible Heart Transplantation Plasma Exchange chart:
- 5% Albumin is recommended when the patient does not require daily exchanges. For daily exchanges, use 5% albumin with FFP to replace clotting factors.
- Octaplasma can be used in cases of reaction to FFP.

Blood prime:
- Blood prime should be
  - patient weight <50kg
  - patient height > 20kg with low hemoglobin (<72g/L)
  - patient who is hemodynamically unstable
- 5% Albumin prime is used for stable patients between 15-20kg as ordered by NRP

Medications
1. Refer to MD orders for specific medications
2. Recommended medication to decrease risk of a reaction to either blood or blood product includes:
   - Benadryl (25mg) IM pre- Achilles when blood prime and FFP ordered (maximum dose: 50mg)
   - Hydrocortisone (50mg IM) with an allergic reaction or previous allergic reaction (maximum dose: 100mg IM in children, 450mg IM/1.25 years, 600mg IM/1.25 years)
   - Calcium Gluconate, please see Management of Citrate Toxicity
   - ACE inhibitors should be withheld for at least 24 hours prior to start of plasma exchange. Long-acting forms of these, including Enalapril and Capoten, should be withheld for 72 hours.

Volume and number of exchanges
1. Recommended volume of exchange is 1-1.5 times plasma volume
2. Procedure to be performed daily for 5 days, then reassessed
3. Improvement in cardiac function, biopsy findings, and donor-specific antibody levels are used to determine timing of discontinuation

Measurement responses:
- ABO incompatible heart transplant decreased anti-HLA antibodies
- HLA sensitized transplant with donor specific antibodies OR non-specific antibody mediated rejection: stabilization or improvement in allograft function

4.0 Related Documents:

Therapeutic Plasma Exchange Procedure
Management of Citrate Toxicity
Blood component Infusions
5.0 References

1. McLeod, B C Apheresis: Principles and Practice. 1997 (409-415)

Attachments:

Heart Transplant_care pathway_Feb 2022 (1).pdf